Anticancer Activity of Half‐Sandwich RhIII and IrIII Metalla‐Prisms Containing Lipophilic Side Chains. Issue 4 (11th March 2014)

• Record Type: Journal Article
• Authors: Gupta, Gajendra; Mahesh Kumar, Jerald; Garci, Amine; Rangaraj, Nandini; Nagesh, Narayana; Therrien, Bruno
• Is Part Of: ChemPlusChem. Volume 79:Issue 4(2014:Apr.)
• Page Start: 610
• Page End: 618
• Publication Date: 2014-03-11
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1002/cplu.201300425
• Languages: English
• ISSNs: 2192-6506

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Two hexacationic pentamethylcyclopentadienyl rhodium(III) and iridium(III) metalla‐prisms, [(η⁵‐C₅Me₅)₆M₆(μ₃‐tpt‐κ<italic>N</italic>)₂(μ₄‐C₆HRO₄‐κ<italic>O</italic>)₃]⁶⁺ (tpt=2, 4, 6‐tri‐(pyridin‐4‐yl)‐1, 3, 5‐triazine; R=(CH₂)₁₀CH₃; M=Rh, [<bold>3</bold>]⁶⁺; M=Ir, [<bold>4</bold>]⁶⁺) isolated as their triflate salts, have been synthesised from the dinuclear complexes (η⁵‐C₅Me₅)₂M₂(μ₄‐C₆HRO₄‐κ<italic>O</italic>)Cl₂ (M=Rh, <bold>1</bold>; M=Ir, <bold>2</bold>) and AgCF₃SO₃. The antiproliferative activity of the neutral and cationic complexes has been evaluated in vitro in human cancer cell lines. The positively charged metalla‐prisms appear to target mitochondria, which ultimately induce apoptosis in cancer cells. All biological studies suggest that the rhodium derivative [<bold>3</bold>][CF₃SO₃]₆ possesses excellent activities, not only in vitro but also in vivo in tumour‐induced C57L6/J mice.</p> </abstract>